Compare Garmin Ltd. (GRMN) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs BIO-TECHNE Corp — how do they compare? Garmin Ltd. trades at $268.36 (market cap $51.77B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Garmin Ltd. is far larger — about 4.6× BIO-TECHNE Corp's market cap, and Garmin Ltd. pays the higher dividend (1.56%). Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and BIO-TECHNE Corp for 64 Days on average.
| GRMN | TECH | |
|---|---|---|
Market Cap | $51.77B | $11.36B |
Volume | 961,398 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $313.16 | $72.61 |
52-Week Low | $187.10 | $43.31 |
Typical Hold Time | 83 Days | 64 Days |
Enterprise Value | $49.28B | $11.39B |
Dividend Yield | 1.56% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $268.44, down 2.8% on the day, amid a bearish technical signal. The stock has demonstrated strong fundamental performance with revenue growing from $4.9B in 2022 to $7.25B in 2025 and net income reaching $1.66B. Recent earnings beats and consistent dividend payments highlight operational strength, while analyst consensus targets $320.25, suggesting potential upside from current levels.
The outlook remains positive given robust profitability and product innovation, but risks include competitive pressures and market volatility. Institutional ownership trends and a Zacks Strong Buy upgrade reflect confidence, yet the stock faces headwinds from broader economic conditions and execution challenges in maintaining growth momentum.
TECH trades at $72.45, near its 52-week high of $72.70 (Defense World, 2026-09-28), with a slight 0.11% decline over 24 hours. The stock shows a bullish technical signal, supported by moving averages, while fundamentals reveal a high P/E of 62.46 and net income margin of 14.97% for 2025. Recent news highlights shareholder approval of its acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23), a key catalyst for near-term price action.
The outlook is mixed: the acquisition offers upside to the current price, but elevated valuation ratios pose risks if earnings growth falters. Analyst consensus is divided with 46% buy ratings, and net income volatility from 2022-2025 signals execution challenges. Investors should weigh the acquisition premium against fundamental sustainability in a competitive life sciences tools sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
